MM cells have high levels of integrin‐α4β1[4] and CD44,[5] which allow them to enter the BM and stimulate the secretion of IL6,[6] promoting their proliferation and inducing monocyte osteoclast differentiation, ultimately leading to immune escape.[7] Despite advancements in treatment, the median survival of MM patients remains less than eight years, potentially due to the limitations of current therapies that only target MM cells. This evidence concerns the gene IL6 and Miyoshi myopathy.